Table 1 Baseline characteristics of the study population

Age^a

Mean ± SD

81.8 ± 7.9 (64 to 96)

Sex^b

Male

18 (37.5%)

Female

30 (62.5%)

Eye^b

OD

25 (47.2%)

OS

28 (52.8%)

Laterality^b

Unilateral

43 (89.6%)

Bilateral

5 (10.4%)

DM^b

Nondiabetic

40 (83.3%)

Diabetic

8 (16.7%)

Phakic status^b

Pseudophakic

37 (69.8%)

Phakic

16 (30.2%)

Legacy^b

L-Bevacizumab

10 (19.2%)

L-Ranibizumab

42 (80.8%)